Galderma Group Future Growth
Future criteria checks 4/6
Galderma Group is forecast to grow earnings and revenue by 44.4% and 11.6% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be 10.2% in 3 years.
Key information
44.4%
Earnings growth rate
45.7%
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 11.6% |
| Future return on equity | 10.2% |
| Analyst coverage | Good |
| Last updated | 19 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 5,706 | 768 | 838 | 1,129 | 10 |
| 12/31/2025 | 4,990 | 495 | 581 | 849 | 11 |
| 12/31/2024 | 4,444 | 226 | 299 | 643 | 11 |
| 6/30/2024 | 4,318 | -14 | 216 | 419 | N/A |
| 3/31/2024 | 4,217 | -36 | 115 | 292 | N/A |
| 12/31/2023 | 4,117 | -57 | 13 | 165 | N/A |
| 12/31/2022 | 3,824 | -97 | -48 | 111 | N/A |
| 12/31/2021 | 3,445 | -82 | 68 | 196 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PY30 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: PY30 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PY30 is expected to become profitable in the next 3 years.
Revenue vs Market: PY30's revenue (11.6% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: PY30's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PY30's Return on Equity is forecast to be low in 3 years time (10.2%).